CD274 and neoplasm: This research reported that the PD-L1 thresholds were variable within or across cancer types using several different assays and PD-L1 expression was also evaluated in a variable fashion either on tumor cells, tumor-infiltrating immune cells, or both, which indicated that PD-L1 expression as a predictive biomarker had shortcomings and that the decision to pursue testing must be carefully implemented for clinical decision-making.